Gan & Lee Pharmaceuticals Co., Ltd. (SSE: 603087.SH) announced on September 9 that the first participant has been dosed in a first-in-human Phase 1 study of GZC8072, an experimental once-weekly oral peptide GLP-1 receptor agonist, marking the compound’s formal entry into human testing. This is an early, safety-focused milestone, not an efficacy result, and no data on how well the drug works, or even how safe it is, will be available for some time.
What This Trial Is Actually Testing
The trial (CTR20263271) is a multicenter, randomized, double-blind, placebo-controlled Phase 1 study with two parts: a single ascending dose portion in healthy adults, and a multiple ascending dose portion in participants who are overweight or have obesity. Gan & Lee plans to enroll 112 participants total, randomized to receive either GZC8072 tablets or a placebo. Trials structured this way are designed primarily to establish a safe dose range and check for early tolerability problems, not to measure whether the drug actually helps people lose weight or control blood sugar; that kind of evidence typically comes later, in Phase 2 and 3 studies. The trial’s registration number, a CTR identifier, indicates it is registered with China’s Center for Drug Evaluation, the regulatory body overseeing clinical trials in the country where this study is being conducted.
The Technology Behind GZC8072
GZC8072 is based on native GLP-1 and is intended, if development succeeds, for both type 2 diabetes and weight management in people who are overweight or have obesity. Gan & Lee says the drug is built on two of its own proprietary technology platforms: NovaPeptide, aimed at the manufacturing challenges of long-acting peptide drugs, and SupOraTide, aimed at getting a peptide, a type of molecule that the digestive system normally breaks down easily, absorbed effectively when taken as a pill rather than injected. The company says combining these platforms gives GZC8072 stronger intrinsic activity, a longer-lasting effect in the body, and meaningfully better oral absorption, supporting once-weekly dosing in tablet form. Those are the company’s own stated design goals for the platform rather than data generated in this trial or any other, since no human results exist yet.
A Crowded Field of Oral GLP-1 Drugs
Gan & Lee frames this launch against a large and growing global health problem: citing World Health Organization figures, the company notes that roughly 2.5 billion adults were overweight in 2022, with that number projected to exceed 2.9 billion by 2030. That backdrop is part of why so much of the pharmaceutical industry is racing to develop easier-to-take versions of GLP-1 therapy. Oral GLP-1 drugs are already a competitive category: Novo Nordisk’s Rybelsus, an oral form of semaglutide, is approved and taken daily, and Eli Lilly’s orforglipron, a once-daily oral small molecule rather than a peptide, has posted Phase 3 weight-loss and diabetes data and is under regulatory review. A once-weekly oral peptide, if GZC8072 eventually works as designed, would aim to combine the convenience of a pill with less frequent dosing than either of those existing daily options, though that combination has not yet been proven to work in humans at all.
Where This Fits in Gan & Lee’s Pipeline
GZC8072 is the newest and least mature entry in a broader Gan & Lee metabolic disease pipeline that already has more advanced, more substantiated programs. Bofanglutide (GZR18), a biweekly injectable GLP-1 receptor agonist, has met its primary endpoints in a Phase III weight-loss study in China and a Phase II study in the U.S., and Gan & Lee has licensed its global commercialization rights outside certain markets to JW Pharmaceutical, a major South Korean drugmaker. Separately, Insulin Ludefen (GZR4), an ultra-long-acting weekly insulin, has met its primary endpoint in a Phase III trial in China. Both of those programs have real, later-stage clinical data behind them; GZC8072 does not yet, and is roughly three clinical phases behind where bofanglutide currently stands. Gan & Lee has historically built its business around insulin products before expanding more recently into GLP-1-based metabolic drugs, giving the company decades of manufacturing and regulatory experience in diabetes care to draw on as it develops this newer pipeline.
What’s Next
Gan & Lee describes this Phase 1 initiation as a milestone for its broader weight management franchise, and says it will continue developing more convenient dosing regimens using its existing technology platforms. No timeline for completing this Phase 1 study, no expected data readout date, and no financial details were disclosed in the release. This article covers an early-stage clinical trial milestone and is not medical or investment advice.
Sources
Gan & Lee Pharmaceuticals: First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA, PRNewswire, September 9, 2026.
Gan & Lee Pharmaceuticals: Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases, cited for background on the company’s stock ticker and more advanced pipeline programs.
Editorial Disclosure
This article is based on a press release issued by Gan & Lee Pharmaceuticals on September 9, 2026, distributed via PRNewswire, with background on the company’s stock ticker and broader pipeline drawn from an earlier Gan & Lee release cited above. Gan & Lee Pharmaceuticals trades on the Shanghai Stock Exchange under the ticker 603087.SH. BioTech Stocks Daily was not compensated for this coverage. Statements regarding GZC8072’s design advantages are the company’s own stated goals rather than data generated in human trials; no efficacy or safety results exist for this compound yet. This article is for informational and educational purposes only, does not constitute investment advice, and is not medical advice. Consult a qualified healthcare professional for medical guidance. See our full DISCLAIMER.
